CO5160243A1 - Formulacion medicamentosa de liberacion retardada que contiene una combinacion de un opioide y un alfa-agonista - Google Patents

Formulacion medicamentosa de liberacion retardada que contiene una combinacion de un opioide y un alfa-agonista

Info

Publication number
CO5160243A1
CO5160243A1 CO00002026A CO00002026A CO5160243A1 CO 5160243 A1 CO5160243 A1 CO 5160243A1 CO 00002026 A CO00002026 A CO 00002026A CO 00002026 A CO00002026 A CO 00002026A CO 5160243 A1 CO5160243 A1 CO 5160243A1
Authority
CO
Colombia
Prior art keywords
opioid
combination
agonist
alfa
delayed release
Prior art date
Application number
CO00002026A
Other languages
English (en)
Inventor
Johannes Bartholomaus
Jurgen Betzing
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of CO5160243A1 publication Critical patent/CO5160243A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Formulación medicamentosa retardada, CARACTERIZADA porque contienen una combinación de un opioide elegido del grupo que comprende morfina, hidromorfona, codeína, oxicodona, dihidrocodeína, dextropropoxifen, buprenorfina, levometadona, fentanil, sufentanil, etorfina, pentazocina, tilidina, tramadol, levorfanol, metadona, dihidromorfina, petidina, piritramida o una sal fisiológicamente tolerable de los mismos; un a-agonista elegido del grupo que comprende clonidina, guanfacina, guanabenz, lofexidina, adrenalina, metildopa, noradrenalina, metoxamina, oximetazolina, xilometazolina, terizolina, ST-91, medetomidina, dexmedetomidina, agmatina, UK14,304, para-amino-clonidina, U-47, 476A, DJ-741, ICI-106270, xilazina, talipexol (BHT-920), nafazolina, tizanidina o una sal fisiológicamente tolerable de los mismos; y lactosa o fosfato monoácido cálcico, con o sin otros excipientes farmacéuticos.
CO00002026A 1999-01-18 2000-01-17 Formulacion medicamentosa de liberacion retardada que contiene una combinacion de un opioide y un alfa-agonista CO5160243A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19901684 1999-01-18

Publications (1)

Publication Number Publication Date
CO5160243A1 true CO5160243A1 (es) 2002-05-30

Family

ID=7894563

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00002026A CO5160243A1 (es) 1999-01-18 2000-01-17 Formulacion medicamentosa de liberacion retardada que contiene una combinacion de un opioide y un alfa-agonista

Country Status (15)

Country Link
US (1) US20020044966A1 (es)
EP (1) EP1143936A2 (es)
JP (1) JP2002534458A (es)
AR (1) AR022252A1 (es)
AU (1) AU772886B2 (es)
BR (1) BR0000578A (es)
CA (1) CA2359273A1 (es)
CO (1) CO5160243A1 (es)
HU (2) HUP0105043A3 (es)
NO (2) NO20000225D0 (es)
NZ (1) NZ513501A (es)
PE (1) PE20001396A1 (es)
SK (1) SK10012001A3 (es)
UY (1) UY25936A1 (es)
WO (1) WO2000041681A2 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2374717T3 (es) 1999-10-29 2012-02-21 Euro-Celtique S.A. Formulaciones de hidrocodona de liberación controlada.
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
CA2424021A1 (en) * 2000-09-29 2002-04-04 Board Of Trustees Operating Michigan State University Catecholamine compositions and uses thereof
KR100960200B1 (ko) 2000-10-30 2010-05-27 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
EP1395243A2 (en) * 2001-05-31 2004-03-10 SkyePharma Inc. Encapsulation of nanosuspensions in liposomes and microspheres
US8329216B2 (en) * 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
KR20030034171A (ko) * 2001-07-06 2003-05-01 엔도 파마슈티걸즈, 인크. 옥시모르폰 제어 방출 제형
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
AU2002337686B2 (en) * 2001-09-26 2008-05-15 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
US7854230B2 (en) * 2001-10-22 2010-12-21 O.R. Solutions, Inc. Heated medical instrument stand with surgical drape and method of detecting fluid and leaks in the stand tray
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US7648981B2 (en) * 2003-02-28 2010-01-19 Ym Biosciences Inc. Opioid delivery system
US7648982B2 (en) * 2003-02-28 2010-01-19 Ym Biosciences Inc. Opioid delivery system
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
US20050100594A1 (en) * 2003-11-12 2005-05-12 Nilendu Sen Pharmaceutical formulation containing muscle relaxant and COX-II inhibitor
DE102005013726A1 (de) * 2005-03-22 2006-09-28 Grünenthal GmbH Transdermale therapeutische Systeme mit verbesserter Verträglichkeit
US7485323B2 (en) * 2005-05-31 2009-02-03 Gelita Ag Process for making a low molecular weight gelatine hydrolysate and gelatine hydrolysate compositions
NZ565649A (en) * 2005-07-28 2011-03-31 Shire Llc Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily
JP5269595B2 (ja) 2005-09-09 2013-08-21 アンジェリーニ ラボファーム リミテッド ライアビリティ カンパニー １日１回投与用トラゾドン組成物
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US20100172991A1 (en) * 2007-06-08 2010-07-08 Henry Joseph Horacek Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
US20090087490A1 (en) 2007-06-08 2009-04-02 Addrenex Pharmaceuticals, Inc. Extended release formulation and method of treating adrenergic dysregulation
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
WO2009130715A1 (en) * 2008-04-25 2009-10-29 Cadila Healtcare Limited Rapidly disintegrating oral compositions of tramadol
EP2309993A1 (en) * 2008-06-25 2011-04-20 US Worldmeds LLC Skin patches and sustained-release formulations comprising lofexidine for transdermal and oral delivery
US8603497B2 (en) * 2008-10-30 2013-12-10 National University Corporation Okayama University Composition for local anesthesia
NZ600640A (en) * 2009-12-17 2014-11-28 Cima Labs Inc Abuse-resistant formulations
EP2568977A1 (en) 2010-05-11 2013-03-20 Cima Labs Inc. Alcohol-resistant metoprolol-containing extended- release oral dosage forms
SG10201510564PA (en) 2010-12-22 2016-01-28 Purdue Pharma Lp Encased tamper resistant controlled release dosage forms
CA2850964C (en) 2011-10-05 2021-02-02 Jennifer L. Sanders Methods and compositions for treating foot or hand pain
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
EP3054935B1 (en) 2013-10-07 2020-12-09 Teikoku Pharma USA, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
RU2646512C2 (ru) 2013-10-07 2018-03-05 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Устройства для трансдермальной доставки дексмедетомидина и способы их применения
RU2648449C2 (ru) 2013-10-07 2018-03-26 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Способы и композиции для трансдермальной доставки неседативного количества дексмедетомидина
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
EP3965733A4 (en) 2019-05-07 2023-01-11 Clexio Biosciences Ltd. ABUSE DETERRENT DOSAGE FORMS CONTAINING ESKETAMINE
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
CN112494486B (zh) * 2020-12-07 2022-01-21 深圳善康医疗健康产业有限公司 一种用于减轻或消除阿片戒断综合症的药物组合物及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946848A (en) * 1985-10-29 1990-08-07 Baker Cumins Dermatologicals, Inc. Method of treating pruritus with nalmefene and clonidine
PT99629A (pt) * 1991-11-28 1993-05-31 Antonio Feria Reis Valle Metodo de desintoxicacao de opiaceos
US5635204A (en) * 1994-03-04 1997-06-03 Montefiore Medical Center Method for transdermal induction of anesthesia, analgesia or sedation
DE19758564A1 (de) * 1997-11-11 1999-08-26 Gruenenthal Gmbh Formulierung einer Kombination aus Morphin und einem alpha¶2¶-adrenergem Agonisten und deren Verwendung

Also Published As

Publication number Publication date
US20020044966A1 (en) 2002-04-18
BR0000578A (pt) 2001-08-14
AU2109000A (en) 2000-08-01
EP1143936A2 (de) 2001-10-17
JP2002534458A (ja) 2002-10-15
UY25936A1 (es) 2001-07-31
WO2000041681A3 (de) 2000-12-07
NO20013302D0 (no) 2001-07-03
PE20001396A1 (es) 2000-12-23
WO2000041681A2 (de) 2000-07-20
NO20000225D0 (no) 2000-01-17
AR022252A1 (es) 2002-09-04
HUP0105043A2 (en) 2002-06-29
HUP0105043A3 (en) 2005-06-28
HU0000139D0 (en) 2000-03-28
NO20013302L (no) 2001-07-03
SK10012001A3 (sk) 2002-01-07
AU772886B2 (en) 2004-05-13
CA2359273A1 (en) 2000-07-20
NZ513501A (en) 2003-11-28

Similar Documents

Publication Publication Date Title
CO5160243A1 (es) Formulacion medicamentosa de liberacion retardada que contiene una combinacion de un opioide y un alfa-agonista
GEP20084485B (en) Matrix for sustained, invariant and independent release of active compounds
WO2004045551A3 (en) Pharmaceutical composition
BRPI0418228A (pt) forma de dosagem, e, métodos de tratamento de dor e de episódios de dor incidente de cáncer, e de preparação de um tablete para administração bucal, gengival ou sublingual de fentanil
CA2547334A1 (en) Methods and compositions for deterring abuse of opioid containing dosage forms
DK0938316T3 (da) Opioidantagonistholdig galenisk formulering
WO2001097780A3 (en) Pharmaceutical compositions comprising an opioid analgesic
AP2005003318A0 (en) Pharmaceutical compositions comprising a basic respectively acidic drug coumpound, a surfactant and a physiologically tolerable watersoluble acid respectively base.
EP1556133A4 (en) TRANSDERMAL DELIVERY SYSTEM FOR WATER-INSOLUBLE DRUGS
PE20031016A1 (es) Sistemas analgesicos transdermicos con potencial de abuso reducido
WO2007013975A3 (en) Composition containing an opioid agonist and a partial opioid agonist, preferably buprenorphine , for controlling abuse of medications
WO2008064202A3 (en) Modified-release formulations of calcium receptor-active compounds
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
WO2003090726A3 (en) Chewable soft capsule
AR085610A1 (es) Formulacion de pelicula bucodispersable estable
JP6279547B2 (ja) オピオイド誘発性有害薬力学的応答を治療するためのシステムおよび方法
AR095160A1 (es) Formulaciones farmacéuticas a prueba de alteraciones
EP1619180A4 (en) CASR ANTAGONIST
WO2003057151A3 (en) A stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof
ATE299019T1 (de) Transdermales therapeutisches system mit einem gehalt an tulobuterol-hydrochlorid zur verabreichung des bronchodilatators tulobuterol über die haut
WO2009035265A3 (en) Calcium phosphate microspheres drug delivery system and process for preparing the same
WO2008115811A4 (en) Transdermal delivery form disposal systems and methods
AU2003297561A8 (en) Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs
RU2012124063A (ru) Лекарственная комбинация с теобромином и ее использование в лечении
TNSN05233A1 (en) Oral pharmaceutical preparation comprising a proton pump antagonist and a basic exipient